Vol. 2 No. 2 (2022)
Reimbursement Recommendations

Daratumumab (Darzalex SC)

Published February 15, 2022

Key Messages

  • CADTH recommends that Darzalex (daratumumab) in combination with cyclophosphamide, bortezomib, and dexamethasone (DCyBorD) should be reimbursed by public drug plans for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis if certain conditions are met.
  • Darzalex should only be covered to treat adult patients with newly diagnosed AL amyloidosis who have good performance status. Patients eligible for reimbursement of Darzalex must not have had prior therapy for AL amyloidosis or multiple myeloma, a previous or current diagnosis of multiple myeloma, or be planning to have a stem cell transplant during the first 6 cycles of treatment with DCyBorD.
  • Darzalex should only be reimbursed if prescribed in combination with cyclophosphamide, bortezomib, and dexamethasone for 6 months, followed by daratumumab alone until the disease progresses or for a maximum of 2 years (whichever comes first), and if the cost of Darzalex is reduced.